Brain Tumor Therapeutics Comprehensive Study by Type (MRI, CT Scan, Tissue Sampling, PET-CT Scan, Cerebral Arteriogram, Lumbar Puncture, Molecular Testing, EEG), Treatment Type (Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy, Immunotherapy, Others), Tumor Type (Primary Brain Tumor, Secondary Brain Tumor) Players and Region - Global Market Outlook to 2026

Brain Tumor Therapeutics Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
The study covers a detailed analysis segmented by key business segments i.e. by type (MRI, CT Scan, Tissue Sampling, PET-CT Scan, Cerebral Arteriogram, Lumbar Puncture, Molecular Testing and EEG) and major geographies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Brain Tumor Therapeutics market throughout the predicted period.

What is Brain Tumor Therapeutics?
Brain tumor therapeutics helps cure abnormal growth of cells inside the brain. Owing to rising cases of brain disorder related death, companies are focusing on developing remedial methods. With over 769,970 estimated cases in United States alone till 2019, brain tumor is causing significant harm to individuals' health. Recently, various therapeutics techniques have been developed yet, a lot has to be done.

The competition is expected to become even more intense in the years to come due to entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Brain Tumor Therapeutics market analysis report suggests strategies Players can follow and recommends key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, including:
  • NOVARTIS [Switzerland]
  • F. HOFFMAN LA-ROCHE LTD. [Switzerland]
  • MERCK & CO. Inc. [United States]
  • IMMUNOCELLULAR THERAPEUTICS LTD. [United States]
  • NOVOCURE [United States]
  • DEL MAR PHARMACEUTICALS INC. [Canada]
  • MOLECULIN BIOTEC. [United States]


Market Trend
Emerging Applications of Gene Therapy in Regenerative Medicine Technological Advances in Regenerative Medicine (Stem Cell, Tissue Engineering, and Nanotechnology)
Restraints
  • High Cost of Treatment and Less Awareness
  • Regulatory and Ethical Issues Pertaining Stem Cell, Tissues Engineering and Regenerative Medicine

Opportunities
High Investment & Funding To Support Development of RM

Key highlights of the Global Brain Tumor Therapeutics market Study:
• CAGR of the market during the forecast period 2020-2026
• In-depth information on growth factors that will accelerate the Brain Tumor Therapeutics market in next few years.
• Detailed Insights on futuristic trends and changing consumer behaviour
• Forecast of the Global Brain Tumor Therapeutics market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Brain Tumor Therapeutics Players

Transformation and Important Trigegrs:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Brain Tumor Therapeutics market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Brain Tumor Therapeutics market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes Healthcare Sectors, Potential Investors, Research Institutes, Government Agencies and Others.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • MRI
  • CT Scan
  • Tissue Sampling
  • PET-CT Scan
  • Cerebral Arteriogram
  • Lumbar Puncture
  • Molecular Testing
  • EEG
By Treatment Type
  • Surgery
  • Radiation Therapy
  • Targeted Therapy
  • Chemotherapy
  • Immunotherapy
  • Others

By Tumor Type
  • Primary Brain Tumor
  • Secondary Brain Tumor

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Adoption of Stem Cell Technology
      • 3.2.2. Growing Prevalence of Chronic Diseases
    • 3.3. Market Trends
      • 3.3.1. Emerging Applications of Gene Therapy in Regenerative Medicine Technological Advances in Regenerative Medicine (Stem Cell, Tissue Engineering, and Nanotechnology)
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Brain Tumor Therapeutics, by Type, Treatment Type, Tumor Type and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Brain Tumor Therapeutics (Value)
      • 5.2.1. Global Brain Tumor Therapeutics by: Type (Value)
        • 5.2.1.1. MRI
        • 5.2.1.2. CT Scan
        • 5.2.1.3. Tissue Sampling
        • 5.2.1.4. PET-CT Scan
        • 5.2.1.5. Cerebral Arteriogram
        • 5.2.1.6. Lumbar Puncture
        • 5.2.1.7. Molecular Testing
        • 5.2.1.8. EEG
      • 5.2.2. Global Brain Tumor Therapeutics by: Treatment Type (Value)
        • 5.2.2.1. Surgery
        • 5.2.2.2. Radiation Therapy
        • 5.2.2.3. Targeted Therapy
        • 5.2.2.4. Chemotherapy
        • 5.2.2.5. Immunotherapy
        • 5.2.2.6. Others
      • 5.2.3. Global Brain Tumor Therapeutics by: Tumor Type (Value)
        • 5.2.3.1. Primary Brain Tumor
        • 5.2.3.2. Secondary Brain Tumor
      • 5.2.4. Global Brain Tumor Therapeutics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Brain Tumor Therapeutics (Price)
      • 5.3.1. Global Brain Tumor Therapeutics by: Type (Price)
  • 6. Brain Tumor Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. NOVARTIS [Switzerland]
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F. HOFFMAN LA-ROCHE LTD. [Switzerland]
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. MERCK & CO. Inc. [United States]
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. IMMUNOCELLULAR THERAPEUTICS LTD. [United States]
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. NOVOCURE [United States]
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. DEL MAR PHARMACEUTICALS INC. [Canada]
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. MOLECULIN BIOTEC. [United States]
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Brain Tumor Therapeutics Sale, by Type, Treatment Type, Tumor Type and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Brain Tumor Therapeutics (Value)
      • 7.2.1. Global Brain Tumor Therapeutics by: Type (Value)
        • 7.2.1.1. MRI
        • 7.2.1.2. CT Scan
        • 7.2.1.3. Tissue Sampling
        • 7.2.1.4. PET-CT Scan
        • 7.2.1.5. Cerebral Arteriogram
        • 7.2.1.6. Lumbar Puncture
        • 7.2.1.7. Molecular Testing
        • 7.2.1.8. EEG
      • 7.2.2. Global Brain Tumor Therapeutics by: Treatment Type (Value)
        • 7.2.2.1. Surgery
        • 7.2.2.2. Radiation Therapy
        • 7.2.2.3. Targeted Therapy
        • 7.2.2.4. Chemotherapy
        • 7.2.2.5. Immunotherapy
        • 7.2.2.6. Others
      • 7.2.3. Global Brain Tumor Therapeutics by: Tumor Type (Value)
        • 7.2.3.1. Primary Brain Tumor
        • 7.2.3.2. Secondary Brain Tumor
      • 7.2.4. Global Brain Tumor Therapeutics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Brain Tumor Therapeutics (Price)
      • 7.3.1. Global Brain Tumor Therapeutics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Brain Tumor Therapeutics: by Type(USD Million)
  • Table 2. Brain Tumor Therapeutics MRI , by Region USD Million (2015-2020)
  • Table 3. Brain Tumor Therapeutics CT Scan , by Region USD Million (2015-2020)
  • Table 4. Brain Tumor Therapeutics Tissue Sampling , by Region USD Million (2015-2020)
  • Table 5. Brain Tumor Therapeutics PET-CT Scan , by Region USD Million (2015-2020)
  • Table 6. Brain Tumor Therapeutics Cerebral Arteriogram , by Region USD Million (2015-2020)
  • Table 7. Brain Tumor Therapeutics Lumbar Puncture , by Region USD Million (2015-2020)
  • Table 8. Brain Tumor Therapeutics Molecular Testing , by Region USD Million (2015-2020)
  • Table 9. Brain Tumor Therapeutics EEG , by Region USD Million (2015-2020)
  • Table 10. Brain Tumor Therapeutics: by Treatment Type(USD Million)
  • Table 11. Brain Tumor Therapeutics Surgery , by Region USD Million (2015-2020)
  • Table 12. Brain Tumor Therapeutics Radiation Therapy , by Region USD Million (2015-2020)
  • Table 13. Brain Tumor Therapeutics Targeted Therapy , by Region USD Million (2015-2020)
  • Table 14. Brain Tumor Therapeutics Chemotherapy , by Region USD Million (2015-2020)
  • Table 15. Brain Tumor Therapeutics Immunotherapy , by Region USD Million (2015-2020)
  • Table 16. Brain Tumor Therapeutics Others , by Region USD Million (2015-2020)
  • Table 17. Brain Tumor Therapeutics: by Tumor Type(USD Million)
  • Table 18. Brain Tumor Therapeutics Primary Brain Tumor , by Region USD Million (2015-2020)
  • Table 19. Brain Tumor Therapeutics Secondary Brain Tumor , by Region USD Million (2015-2020)
  • Table 20. South America Brain Tumor Therapeutics, by Country USD Million (2015-2020)
  • Table 21. South America Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 22. South America Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 23. South America Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 24. Brazil Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 25. Brazil Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 26. Brazil Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 27. Argentina Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 28. Argentina Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 29. Argentina Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 30. Rest of South America Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 31. Rest of South America Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 32. Rest of South America Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 33. Asia Pacific Brain Tumor Therapeutics, by Country USD Million (2015-2020)
  • Table 34. Asia Pacific Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 35. Asia Pacific Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 36. Asia Pacific Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 37. China Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 38. China Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 39. China Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 40. Japan Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 41. Japan Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 42. Japan Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 43. India Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 44. India Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 45. India Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 46. South Korea Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 47. South Korea Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 48. South Korea Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 49. Taiwan Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 50. Taiwan Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 51. Taiwan Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 52. Australia Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 53. Australia Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 54. Australia Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 55. Rest of Asia-Pacific Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 56. Rest of Asia-Pacific Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 57. Rest of Asia-Pacific Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 58. Europe Brain Tumor Therapeutics, by Country USD Million (2015-2020)
  • Table 59. Europe Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 60. Europe Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 61. Europe Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 62. Germany Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 63. Germany Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 64. Germany Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 65. France Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 66. France Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 67. France Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 68. Italy Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 69. Italy Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 70. Italy Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 71. United Kingdom Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 72. United Kingdom Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 73. United Kingdom Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 74. Netherlands Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 75. Netherlands Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 76. Netherlands Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 77. Rest of Europe Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 78. Rest of Europe Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 79. Rest of Europe Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 80. MEA Brain Tumor Therapeutics, by Country USD Million (2015-2020)
  • Table 81. MEA Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 82. MEA Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 83. MEA Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 84. Middle East Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 85. Middle East Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 86. Middle East Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 87. Africa Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 88. Africa Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 89. Africa Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 90. North America Brain Tumor Therapeutics, by Country USD Million (2015-2020)
  • Table 91. North America Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 92. North America Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 93. North America Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 94. United States Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 95. United States Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 96. United States Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 97. Canada Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 98. Canada Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 99. Canada Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 100. Mexico Brain Tumor Therapeutics, by Type USD Million (2015-2020)
  • Table 101. Mexico Brain Tumor Therapeutics, by Treatment Type USD Million (2015-2020)
  • Table 102. Mexico Brain Tumor Therapeutics, by Tumor Type USD Million (2015-2020)
  • Table 103. Brain Tumor Therapeutics: by Type(USD/Units)
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Brain Tumor Therapeutics: by Type(USD Million)
  • Table 112. Brain Tumor Therapeutics MRI , by Region USD Million (2021-2026)
  • Table 113. Brain Tumor Therapeutics CT Scan , by Region USD Million (2021-2026)
  • Table 114. Brain Tumor Therapeutics Tissue Sampling , by Region USD Million (2021-2026)
  • Table 115. Brain Tumor Therapeutics PET-CT Scan , by Region USD Million (2021-2026)
  • Table 116. Brain Tumor Therapeutics Cerebral Arteriogram , by Region USD Million (2021-2026)
  • Table 117. Brain Tumor Therapeutics Lumbar Puncture , by Region USD Million (2021-2026)
  • Table 118. Brain Tumor Therapeutics Molecular Testing , by Region USD Million (2021-2026)
  • Table 119. Brain Tumor Therapeutics EEG , by Region USD Million (2021-2026)
  • Table 120. Brain Tumor Therapeutics: by Treatment Type(USD Million)
  • Table 121. Brain Tumor Therapeutics Surgery , by Region USD Million (2021-2026)
  • Table 122. Brain Tumor Therapeutics Radiation Therapy , by Region USD Million (2021-2026)
  • Table 123. Brain Tumor Therapeutics Targeted Therapy , by Region USD Million (2021-2026)
  • Table 124. Brain Tumor Therapeutics Chemotherapy , by Region USD Million (2021-2026)
  • Table 125. Brain Tumor Therapeutics Immunotherapy , by Region USD Million (2021-2026)
  • Table 126. Brain Tumor Therapeutics Others , by Region USD Million (2021-2026)
  • Table 127. Brain Tumor Therapeutics: by Tumor Type(USD Million)
  • Table 128. Brain Tumor Therapeutics Primary Brain Tumor , by Region USD Million (2021-2026)
  • Table 129. Brain Tumor Therapeutics Secondary Brain Tumor , by Region USD Million (2021-2026)
  • Table 130. South America Brain Tumor Therapeutics, by Country USD Million (2021-2026)
  • Table 131. South America Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 132. South America Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 133. South America Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 134. Brazil Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 135. Brazil Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 136. Brazil Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 137. Argentina Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 138. Argentina Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 139. Argentina Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 140. Rest of South America Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 141. Rest of South America Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 142. Rest of South America Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 143. Asia Pacific Brain Tumor Therapeutics, by Country USD Million (2021-2026)
  • Table 144. Asia Pacific Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 145. Asia Pacific Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 146. Asia Pacific Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 147. China Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 148. China Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 149. China Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 150. Japan Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 151. Japan Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 152. Japan Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 153. India Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 154. India Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 155. India Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 156. South Korea Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 157. South Korea Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 158. South Korea Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 159. Taiwan Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 160. Taiwan Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 161. Taiwan Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 162. Australia Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 163. Australia Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 164. Australia Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 165. Rest of Asia-Pacific Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 166. Rest of Asia-Pacific Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 167. Rest of Asia-Pacific Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 168. Europe Brain Tumor Therapeutics, by Country USD Million (2021-2026)
  • Table 169. Europe Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 170. Europe Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 171. Europe Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 172. Germany Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 173. Germany Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 174. Germany Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 175. France Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 176. France Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 177. France Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 178. Italy Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 179. Italy Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 180. Italy Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 181. United Kingdom Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 182. United Kingdom Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 183. United Kingdom Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 184. Netherlands Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 185. Netherlands Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 186. Netherlands Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 187. Rest of Europe Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 188. Rest of Europe Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 189. Rest of Europe Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 190. MEA Brain Tumor Therapeutics, by Country USD Million (2021-2026)
  • Table 191. MEA Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 192. MEA Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 193. MEA Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 194. Middle East Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 195. Middle East Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 196. Middle East Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 197. Africa Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 198. Africa Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 199. Africa Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 200. North America Brain Tumor Therapeutics, by Country USD Million (2021-2026)
  • Table 201. North America Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 202. North America Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 203. North America Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 204. United States Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 205. United States Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 206. United States Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 207. Canada Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 208. Canada Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 209. Canada Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 210. Mexico Brain Tumor Therapeutics, by Type USD Million (2021-2026)
  • Table 211. Mexico Brain Tumor Therapeutics, by Treatment Type USD Million (2021-2026)
  • Table 212. Mexico Brain Tumor Therapeutics, by Tumor Type USD Million (2021-2026)
  • Table 213. Brain Tumor Therapeutics: by Type(USD/Units)
  • Table 214. Research Programs/Design for This Report
  • Table 215. Key Data Information from Secondary Sources
  • Table 216. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Brain Tumor Therapeutics: by Type USD Million (2015-2020)
  • Figure 5. Global Brain Tumor Therapeutics: by Treatment Type USD Million (2015-2020)
  • Figure 6. Global Brain Tumor Therapeutics: by Tumor Type USD Million (2015-2020)
  • Figure 7. South America Brain Tumor Therapeutics Share (%), by Country
  • Figure 8. Asia Pacific Brain Tumor Therapeutics Share (%), by Country
  • Figure 9. Europe Brain Tumor Therapeutics Share (%), by Country
  • Figure 10. MEA Brain Tumor Therapeutics Share (%), by Country
  • Figure 11. North America Brain Tumor Therapeutics Share (%), by Country
  • Figure 12. Global Brain Tumor Therapeutics: by Type USD/Units (2015-2020)
  • Figure 13. Global Brain Tumor Therapeutics share by Players 2020 (%)
  • Figure 14. Global Brain Tumor Therapeutics share by Players (Top 3) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. NOVARTIS [Switzerland] Revenue, Net Income and Gross profit
  • Figure 17. NOVARTIS [Switzerland] Revenue: by Geography 2020
  • Figure 18. F. HOFFMAN LA-ROCHE LTD. [Switzerland] Revenue, Net Income and Gross profit
  • Figure 19. F. HOFFMAN LA-ROCHE LTD. [Switzerland] Revenue: by Geography 2020
  • Figure 20. MERCK & CO. Inc. [United States] Revenue, Net Income and Gross profit
  • Figure 21. MERCK & CO. Inc. [United States] Revenue: by Geography 2020
  • Figure 22. IMMUNOCELLULAR THERAPEUTICS LTD. [United States] Revenue, Net Income and Gross profit
  • Figure 23. IMMUNOCELLULAR THERAPEUTICS LTD. [United States] Revenue: by Geography 2020
  • Figure 24. NOVOCURE [United States] Revenue, Net Income and Gross profit
  • Figure 25. NOVOCURE [United States] Revenue: by Geography 2020
  • Figure 26. DEL MAR PHARMACEUTICALS INC. [Canada] Revenue, Net Income and Gross profit
  • Figure 27. DEL MAR PHARMACEUTICALS INC. [Canada] Revenue: by Geography 2020
  • Figure 28. MOLECULIN BIOTEC. [United States] Revenue, Net Income and Gross profit
  • Figure 29. MOLECULIN BIOTEC. [United States] Revenue: by Geography 2020
  • Figure 30. Global Brain Tumor Therapeutics: by Type USD Million (2021-2026)
  • Figure 31. Global Brain Tumor Therapeutics: by Treatment Type USD Million (2021-2026)
  • Figure 32. Global Brain Tumor Therapeutics: by Tumor Type USD Million (2021-2026)
  • Figure 33. South America Brain Tumor Therapeutics Share (%), by Country
  • Figure 34. Asia Pacific Brain Tumor Therapeutics Share (%), by Country
  • Figure 35. Europe Brain Tumor Therapeutics Share (%), by Country
  • Figure 36. MEA Brain Tumor Therapeutics Share (%), by Country
  • Figure 37. North America Brain Tumor Therapeutics Share (%), by Country
  • Figure 38. Global Brain Tumor Therapeutics: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • NOVARTIS [Switzerland]
  • F. HOFFMAN LA-ROCHE LTD. [Switzerland]
  • MERCK & CO. Inc. [United States]
  • IMMUNOCELLULAR THERAPEUTICS LTD. [United States]
  • NOVOCURE [United States]
  • DEL MAR PHARMACEUTICALS INC. [Canada]
  • MOLECULIN BIOTEC. [United States]
Additional players considered in the study are as follows:
Siemens Healthineers [Germany] , Hitachi Healthcare [United States] , Philips Healthcare [Netherlands] , Canon Medical Systems Corporation [Japan] , Shimadzu Corp [Japan]
Select User Access Type

Key Highlights of Report


Dec 2021 200 Pages 96 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Brain Tumor Therapeutics Market is heading robustly to achieve new growth cycle.
The Concentration Rate of Global Brain Tumor Therapeutics market is dominated by United States Players to generate healthy valuation by 2026.
Companies that are profiled in Global Brain Tumor Therapeutics Market are NOVARTIS [Switzerland], F. HOFFMAN LA-ROCHE LTD. [Switzerland], MERCK & CO. Inc. [United States], IMMUNOCELLULAR THERAPEUTICS LTD. [United States], NOVOCURE [United States], DEL MAR PHARMACEUTICALS INC. [Canada] and MOLECULIN BIOTEC. [United States] etc.

Know More About Global Brain Tumor Therapeutics Market Report?